@LifeSciVC@drrichjlaw Inlicensing (regardless of source) creates companies - employing people - and more shots on goal for better therapies for patients
Following breakthrough results, we’re bringing longevity medicine to human trials.
We’ve raised a $435M Series C led by @foundersfund to make it happen.
Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it.
The drug that got a 3 minute standing ovation yesterday at ASCO did not originate from China. On the other hand, the oncology drug that did come from China, with a lot of fanfare, deeply disappointed in PH3.
@oakazaki@FlagshipPioneer Not apples to apples comparison - Flagship goes after tough areas/innovations (CGT, vaccines, etc.) and to my knowledge, other than @Curie_Bio, does zero Chinese VC wrappers (ie newcos) or invest in China.
The success stories of biotech VC are remarkable.
The rate of successful exits in that category, even controlling for the survivorship bias of more intensive pre-incorporation periods, is outstanding.
@FlagshipPioneer is one of the best examples. From their Fund IV, in 2012, they made ~35 investments and produced 11 IPOs with a combined market cap of ~$14B.
This kind of performance doesn't happen by chance. Flagship's Founder and CEO, @NoubarAfeyan, has devoted his career to making innovation more process-oriented and systematic.
@biotech_bro@FlagshipPioneer TBH We can debate that about a large percentage of 2018-2021 biotechs - I was highlighting a strong liquidity event % for its portcos.